SPMS Patient First To Be Treated With Antibody Given via Nasal Spray

SPMS Patient First To Be Treated With Antibody Given via Nasal Spray

290881

SPMS Patient First To Be Treated With Antibody Given via Nasal Spray

For a first time, an immune-modulating antibody will be given via nasal administration to treat a person with secondary progressive multiple sclerosis (SPMS). The U.S. Food and Drug Administration (FDA) approved a request to use the antibody — a fully human anti-CD3 monoclonal antibody called foralumab — under an Individual Patient Expanded Access Program, the therapy’s developer, Tiziana Life Sciences, announced in a press release. Treatment is expected to begin by late June, and last for…

You must be logged in to read/download the full post.